Press Kit

A newly developing, easy, fast, accurate screening for chronic kidney disease (CKD), especially for asymptomatic patients. As you know, early detection of CKD provides an opportunity to slow CKD progression; and 2015 CKD healthcare costs paid by Medicare alone were over $98 billion. The fact sheet explains the new procedure being developed by DialySensors Inc. It starts with a simple, one-time collected urine sample that is then scanned using Raman spectrometry. The Raman spectra data is reduced using the company’s proprietary Rametrix™ Computational Pipeline tool, resulting in a numerical value related to a patient’s CKD status and stage. The test is certainly compatible with current patient urine testing activities performed by medical test laboratories. To date, the company has completed two 50-patient studies that show a >95% sensitivity and >95% specificity in detecting late-stage CKD, and the ability to distinguish among CKD stages.

DialySensors is currently preparing more extensive, larger patient studies.